Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
16 May
Rein <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc reports results for the quarter ended March 31 - Earnings Summary
  • Rein Therapeutics Inc RNTX.OQ reported a quarterly adjusted loss of 25 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -86 cents. The mean expectation of two analysts for the quarter was for a loss of 24 cents per share. Wall Street expected results to range from -28 cents to -21 cents per share.

  • Reported revenue was zero​; analysts expected zero.

  • Rein Therapeutics Inc's reported EPS for the quarter was a loss of 25 cents​.

  • The company reported a quarterly loss of $5.5 million.

  • Rein Therapeutics Inc shares had risen by 33.3% this quarter and gained 2.6% so far this year.

FORECAST CHANGES

  • In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

  • Wall Street's median 12-month price target for Rein Therapeutics Inc is $10.00

This summary was machine generated from LSEG data May 16 at 08:02 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING

ESTIMATE

ACTUAL

BEAT, MET, MISSED

Mar. 31 2025

-0.24

-0.25

Missed

Dec. 31 2024

-0.14

-2.20

Missed

Sep. 30 2024

-0.41

-0.27

Beat

Jun. 30 2024

-0.42

-0.45

Missed

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10